Natural antimicrobial peptides from bacteria: Characteristics and potential applications to fight against antibiotic resistance

Journal of Applied Microbiology

Volumn 113, Issue 4, 2012, Pages 723-736

  Hassan, M ^a,b   Kjos, M ^c   Nes, I F ^c   Diep, D B ^c   Lotfipour, F ^a,d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibiotic resistance; Antimicrobial peptides; Bacteriocins; Drug therapy; Prokaryote

Indexed keywords

ANTIMICROBIAL AGENTS; BACTERIA; CONTROLLED DRUG DELIVERY; PEPTIDES;

ANTIBIOTICS RESISTANCE; ANTIMICROBIAL PEPTIDE; BACTERIOCINS; HIGH POTENCY; INFECTIOUS DISEASE; NANOMOLAR CONCENTRATION; NATURAL-ANTIMICROBIALS; PORE FORMATION; PROKARYOTE; TARGET CELLS;

ANTIBIOTICS;

ABP 118; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL VACCINE; BACTERIOCIN; COLICIN; COLICIN V; ENTEROCIN A; ENTEROCIN P; LACTICIN 3147; LACTOCOCCIN; LACTOCOCCIN G; LANTIBIOTIC; LEUCOCIN A; MESENTERICIN Y105; MICROCIN C7; MICROCIN DERIVATIVE; MICROCIN E492; MICROCIN J25; NISIN; NONLANTIBIOTIC; OXAZOLIDINONE DERIVATIVE; PEDIOCIN; PEDIOCIN PA 1; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; SUBTILIN; THURICIN; THURICIN CD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIUM; EMERGENCE; HOST-PATHOGEN INTERACTION; PEPTIDE; PROBIOTICS; PROKARYOTE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AWARENESS; BACTERIAL CELL; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM; CHEMICAL STRUCTURE; DISEASE CONTROL; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; ESCHERICHIA COLI; GENE MUTATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROFLORA; NONHUMAN; PATHOGENESIS; PENICILLIN RESISTANCE; PHYSICIAN; PSEUDOMONAS AERUGINOSA; REVIEW; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION;

PROKARYOTA;

EID: 84866290009     PISSN: 13645072     EISSN: 13652672     Source Type: Journal    
DOI: 10.1111/j.1365-2672.2012.05338.x     Document Type: Review

References (135)

1. Abachin, E., Poyart, C., Pellegrini, E., Milohanic, E., Fiedler, F., Berche, P. and Trieu-Cuot, P. (2002) Formation of D-alanyl-lipoteichoic acid is required for adhesion and virulence of Listeria monocytogenes. Mol Microbiol 43, 1-14.
2. Andriole, V.T. (2005) The quinolones: past, present, and future. Clin Infect Dis 41(Suppl 2), S113-S119.
3. Aslam, S., Hamill, R.J. and Musher, D.M. (2005) Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 5, 549-557.
4. Bastos, M.C.F., Coutinho, B.G. and Coelho, M.L.V. (2010) Lysostaphin: a staphylococcal bacteriolysin with potential clinical applications. Pharmaceuticals 3, 1139-1161.
5. Bavin, E.M., Beach, A.S., Falconer, R. and Friedmann, R. (1952) Nisin in experimental tuberculosis. Lancet 1, 127-129.
6. Belguesmia, Y., Madi, A., Sperandio, D., Merieau, A., Feuilloley, M., Prevost, H., Drider, D. and Connil, N. (2011) Growing insights into the safety of bacteriocins: the case of enterocin S37. Res Microbiol 162, 159-163.
7. Bierbaum, G. and Sahl, H.G. (2009) Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol 10, 2-18.
8. Bonelli, R.R., Wiedemann, I. and Sahl, H.G. (2006) Lantibiotics, including nisin. In Handbook of Biologically Active Peptides ed. Kastin, A.J. pp. 1139-1145. San Diego, CA: Academic Press.
9. Boyle-Vavra, S. and Daum, R.S. (2007) Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 87, 3-9.
10. Breukink, E. and de Kruijff, B. (2006) Lipid II as a target for antibiotics. Nat Rev Drug Discov 5, 321-332.
11. Brotz, H., Bierbaum, G., Leopold, K., Reynolds, P.E. and Sahl, H.G. (1998a) The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob Agents Chemother 42, 154-160.
12. Brotz, H., Josten, M., Wiedemann, I., Schneider, U., Gotz, F., Bierbaum, G. and Sahl, H.G. (1998b) Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol 30, 317-327.
13. Campelo, A.B., Gaspar, P., Roces, C., Rodriguez, A., Kok, J., Kuipers, O.P., Neves, A.R. and Martinez, B. (2011) The Lcn972-bacteriocin plasmid pBL1 impairs cellobiose metabolism in Lactococcus lactis. Appl Environ Microbiol, 77, 7576-7585.
14. Casey, P.G., Gardiner, G.E., Casey, G., Bradshaw, B., Lawlor, P.G., Lynch, P.B., Leonard, F.C., Stanton, C., Ross, R.P., Fitzgerald, G.F. and Hill, C. (2007) A five-strain probiotic combination reduces pathogen shedding and alleviates disease signs in pigs challenged with Salmonella enterica Serovar Typhimurium. Appl Environ Microbiol 73, 1858-1863.
15. Cheng, Y., Xu, Z., Ma, M. and Xu, T. (2008) Dendrimers as drug carriers: applications in different routes of drug administration. J Pharm Sci 97, 123-143.
16. Coconnier, M.H., Lievin, V., Hemery, E. and Servin, A.L. (1998) Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol 64, 4573-4580.
17. Collado, M.C., Isolauri, E., Salminen, S. and Sanz, Y. (2009) The impact of probiotic on gut health. Curr Drug Metab 10, 68-78.
18. Corr, S.C., Gahan, C.G. and Hill, C. (2007a) Impact of selected Lactobacillus and Bifidobacterium species on Listeria monocytogenes infection and the mucosal immune response. FEMS Immunol Med Microbiol 50, 380-388.
19. Corr, S.C., Li, Y., Riedel, C.U., O'Toole, P.W., Hill, C. and Gahan, C.G.M. (2007b) Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 104, 7617-7621.
20. Cotter, P.D., Hill, C. and Ross, R.P. (2005a) Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Pept Sci 6, 61-75.
21. Cotter, P.D., Hill, C. and Ross, R.P. (2005b) Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 3, 777-788.
22. Cruchet, S., Obregon, M.C., Salazar, G., Diaz, E. and Gotteland, M. (2003) Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition 19, 716-721.
23. Dajcs, J.J., Thibodeaux, B.A., Girgis, D.O., Shaffer, M.D., Delvisco, S.M. and O'Callaghan, R.J. (2002) Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Invest Ophthalmol Vis Sci 43, 3712-3716.
24. De Vuyst, L. and Leroy, F. (2007) Bacteriocins from lactic acid bacteria: production, purification, and food applications. J Mol Microbiol Biotechnol 13, 194-199.
25. Demain, A.L. (2002) Prescription for an ailing pharmaceutical industry. Nat Biotech 20, 331-331.
26. Diaz, M., Valdivia, E., Martinez-Bueno, M., Fernandez, M., Soler-Gonzalez, A.S., Ramirez-Rodrigo, H. and Maqueda, M. (2003) Characterization of a new operon, as-48EFGH, from the as-48 gene cluster involved in immunity to enterocin AS-48. Appl Environ Microbiol 69, 1229-1236.
27. Diep, D.B., Skaugen, M., Salehian, Z., Holo, H. and Nes, I.F. (2007) Common mechanisms of target cell recognition and immunity for class II bacteriocins. Proc Natl Acad Sci USA 104, 2384-2389.
28. Dixon, R.E., Goodman, J.S. and Koenig, M.G. (1968) Lysostaphin: an enzymatic approach to staphylococcal disease. 3. Combined lysostaphin-methicillin therapy of established staphylococcal abscesses in mice. Yale J Biol Med 41, 62-68.
29. Draper, L.A., Ross, R.P., Hill, C. and Cotter, P.D. (2008) Lantibiotic immunity. Curr Protein Pept Sci 9, 39-49.
30. Dufes, C., Uchegbu, I.F. and Schatzlein, A.G. (2005) Dendrimers in gene delivery. Adv Drug Deliv Rev 57, 2177-2202.
31. Duquesne, S., Destoumieux-Garzon, D., Peduzzi, J. and Rebuffat, S. (2007) Microcins, gene-encoded antibacterial peptides from enterobacteria. Nat Prod Rep 24, 708-734.
32. Eijsink, V.G., Skeie, M., Middelhoven, P.H., Brurberg, M.B. and Nes, I.F. (1998) Comparative studies of class IIa bacteriocins of lactic acid bacteria. Appl Environ Microbiol 64, 3275-3281.
33. Eijsink, V.G.H., Axelsson, L., Diep, D.B., Havarstein, L.S., Holo, H. and Nes, I.F. (2002) Production of class II bacteriocins by lactic acid bacteria; an example of biological warfare and communication. Antonie Van Leeuwenhoek 81, 639-654.
34. Ernst, C.M. and Peschel, A. (2011) Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids. Mol Microbiol 80, 290-299.
35. Finch, R. and Hunter, P.A. (2006) Antibiotic resistance-action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005. J Antimicrob Chemother 58(Suppl 1), i3-i22.
36. Fregeau Gallagher, N.L., Sailer, M., Niemczura, W.P., Nakashima, T.T., Stiles, M.E. and Vederas, J.C. (1997) Three-dimensional structure of leucocin A in trifluoroethanol and dodecylphosphocholine micelles: spatial location of residues critical for biological activity in type IIa bacteriocins from lactic acid bacteria. Biochemistry 36, 15062-15072.
37. Gillor, O., Kirkup, B.C. and Riley, M.A. (2004) Colicins and microcins: the next generation antimicrobials. Adv Appl Microbiol 54, 129-146.
38. Gillor, O., Etzion, A. and Riley, M.A. (2008) The dual role of bacteriocins as anti- and probiotics. Appl Microbiol Biotechnol 81, 591-606.
39. Goldstein, B.P., Wei, J., Greenberg, K. and Novick, R. (1998) Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model. J Antimicrob Chemother 42, 277-278.
40. Graham, S. and Coote, P.J. (2007) Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin. J Antimicrob Chemother 59, 759-762.
41. Gravesen, A., Jydegaard Axelsen, A.M., Mendes da Silva, J., Hansen, T.B. and Knochel, S. (2002a) Frequency of bacteriocin resistance development and associated fitness costs in Listeria monocytogenes. Appl Environ Microbiol 68, 756-764.
42. Gravesen, A., Ramnath, M., Rechinger, K.B., Andersen, N., Jansch, L., Hechard, Y., Hastings, J.W. and Knochel, S. (2002b) High-level resistance to class IIa bacteriocins is associated with one general mechanism in Listeria monocytogenes. Microbiology (Reading, England) 148, 2361-2369.
43. Gravesen, A., Kallipolitis, B., Holmstrom, K., Hoiby, P.E., Ramnath, M. and Knochel, S. (2004) pbp2229-mediated nisin resistance mechanism in Listeria monocytogenes confers cross-protection to class IIa bacteriocins and affects virulence gene expression. Appl Environ Microbiol 70, 1669-1679.
44. Guani-Guerra, E., Santos-Mendoza, T., Lugo-Reyes, S.O. and Teran, L.M. (2010) Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol 135, 1-11.
45. Harrison, E.F. and Zygmunt, W.A. (1967) Lysostaphin in experimental renal infections. J Bacteriol 93, 520-524.
46. Hasper, H.E., Kramer, N.E., Smith, J.L., Hillman, J.D., Zachariah, C., Kuipers, O.P., de Kruijff, B. and Breukink, E. (2006) An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 313, 1636-1637.
47. Haugen, H.S., Fimland, G., Nissen-Meyer, J. and Kristiansen, P.E. (2005) Three-dimensional structure in lipid micelles of the pediocin-like antimicrobial peptide curvacin A. Biochemistry 44, 16149-16157.
48. Havarstein, L.S., Holo, H. and Nes, I.F. (1994) The leader peptide of colicin V shares consensus sequences with leader peptides that are common among peptide bacteriocins produced by gram-positive bacteria. Microbiology, 142(Pt 9), 2383-2389.
49. Héchard, Y. and Sahl, H.-G. (2002) Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria. Biochimie 84, 545-557.
50. van Hemert, S., Meijerink, M., Molenaar, D., Bron, P.A., de Vos, P., Kleerebezem, M., Wells, J.M. and Marco, M.L. (2010) Identification of Lactobacillus plantarum genes modulating the cytokine response of human peripheral blood mononuclear cells. BMC Microbiol 10, 293.
51. Howell, T.H., Fiorellini, J.P., Blackburn, P., Projan, S.J., de la Harpe, J. and Williams, R.C. (1993) The effect of a mouthrinse based on nisin, a bacteriocin, on developing plaque and gingivitis in beagle dogs. J Clin Periodontol 20, 335-339.
52. Hsu, S.T., Breukink, E., Tischenko, E., Lutters, M.A., de Kruijff, B., Kaptein, R., Bonvin, A.M. and van Nuland, N.A. (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat Struct Mol Biol 11, 963-967.
53. Jack, R.W., Tagg, J.R. and Ray, B. (1995) Bacteriocins of gram-positive bacteria. Microbiol Rev 59, 171-200.
54. Janiszewska, J. and Urbanczyk-Lipkowska, Z. (2007) Amphiphilic dendrimeric peptides as model non-sequential pharmacophores with antimicrobial properties. J Mol Microbiol Biotechnol 13, 220-225.
55. Johnsen, L., Fimland, G. and Nissen-Meyer, J. (2005) The C-terminal domain of pediocin-like antimicrobial peptides (class IIa bacteriocins) is involved in specific recognition of the C-terminal part of cognate immunity proteins and in determining the antimicrobial spectrum. J Biol Chem 280, 9243-9250.
56. de Jong, A., van Heel, A.J., Kok, J. and Kuipers, O.P. (2010) BAGEL2: mining for bacteriocins in genomic data. Nucleic Acids Res 38, W647-W651.
57. Karchmer, A.W. (2004) Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US-an update. Clin Infect Dis 39(Suppl 3), S142-S150.
58. Kemperman, R., Kuipers, A., Karsens, H., Nauta, A., Kuipers, O. and Kok, J. (2003) Identification and characterization of two novel clostridial bacteriocins, circularin A and closticin 574. Appl Environ Microbiol 69, 1589-1597.
59. Kjos, M., Nes, I.F. and Diep, D.B. (2009) Class II one-peptide bacteriocins target a phylogenetically defined subgroup of mannose phosphotransferase systems on sensitive cells. Microbiology 155, 2949-2961.
60. Kjos, M., Salehian, Z., Nes, I.F. and Diep, D.B. (2010a) An extracellular loop of the mannose phosphotransferase system component IIC is responsible for specific targeting by class IIa bacteriocins. J Bacteriol 192, 5906-5913.
61. Kjos, M., Snipen, L., Salehian, Z., Nes, I.F. and Diep, D.B. (2010b) The Abi proteins and their involvement in bacteriocin self-immunity. J Bacteriol 192, 2068-2076.
62. Kjos, M., Borrero, J., Opsata, M., Birri, D.J., Holo, H., Cintas, L.M., Snipen, L., Hernandez, P.E., Nes, I.F. and Diep, D.B. (2011a) Target recognition, resistance, immunity and genome mining of class II bacteriocins from Gram-positive bacteria. Microbiology (Reading, England) 157, 3256-3267.
63. Kjos, M., Nes, I.F. and Diep, D.B. (2011b) Mechanisms of resistance to bacteriocins targeting the mannose phosphotransferase system. Appl Environ Microbiol 77, 3335-3342.
64. Kokai-Kun, J.F., Walsh, S.M., Chanturiya, T. and Mond, J.J. (2003) Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 47, 1589-1597.
65. Kokai-Kun, J.F., Chanturiya, T. and Mond, J.J. (2009) Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J Antimicrob Chemother 64, 94-100.
66. Kramer, N.E., van Hijum, S.A.F.T., Knol, J., Kok, J. and Kuipers, O.P. (2006) Transcriptome analysis reveals mechanisms by which Lactococcus lactis acquires nisin resistance. Antimicrob Agents Chemother 50, 1753-1761.
67. Kruszewska, D., Sahl, H.G., Bierbaum, G., Pag, U., Hynes, S.O. and Ljungh, A. (2004) Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother 54, 648-653.
68. Kundig, W., Ghosh, S. and Roseman, S. (1964) Phosphate bound to histidine in a protein as an intermediate in a novel phosphotransferase system. Proc Natl Acad Sci USA 52, 1067-1074.
69. Lavina, M., Gaggero, C. and Moreno, F. (1990) Microcin H47, a chromosome-encoded microcin antibiotic of Escherichia coli. J Bacteriol 172, 6585-6588.
70. Leibovici, L., Paul, M. and Ezra, O. (2011) Ethical dilemmas in antibiotic treatment. J Antimicrob Chemother 67, 6-12.
71. Lesbros-Pantoflickova, D., Corthesy-Theulaz, I. and Blum, A.L. (2007) Helicobacter pylori and probiotics. J Nutr 137, 812S-818S.
72. Lopez, F.E., Vincent, P.A., Zenoff, A.M., Salomon, R.A. and Farias, R.N. (2007) Efficacy of microcin J25 in biomatrices and in a mouse model of Salmonella infection. J Antimicrob Chemother 59, 676-680.
73. de Lorenzo, V. (1984) Isolation and characterization of microcin E492 from Klebsiella pneumoniae. Arch Microbiol 139, 72-75.
74. Lubelski, J., Rink, R., Khusainov, R., Moll, G.N. and Kuipers, O.P. (2008) Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell Mol Life Sci 65, 455-476.
75. Madsen, K., Cornish, A., Soper, P., McKaigney, C., Jijon, H., Yachimec, C., Doyle, J., Jewell, L. and De Simone, C. (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121, 580-591.
76. Martinez, B., Bottiger, T., Schneider, T., Rodriguez, A., Sahl, H.G. and Wiedemann, I. (2008) Specific interaction of the unmodified bacteriocin lactococcin 972 with the cell wall precursor lipid II. Appl Environ Microbiol 74, 4666-4670.
77. Meijerink, M., van Hemert, S., Taverne, N., Wels, M., de Vos, P., Bron, P.A., Savelkoul, H.F., van Bilsen, J., Kleerebezem, M. and Wells, J.M. (2010) Identification of genetic loci in Lactobacillus plantarum that modulate the immune response of dendritic cells using comparative genome hybridization. PLoS ONE 5, e10632.
78. Millette, M., Cornut, G., Dupont, C., Shareck, F., Archambault, D. and Lacroix, M. (2008) Capacity of human nisin- and pediocin-producing lactic Acid bacteria to reduce intestinal colonization by vancomycin-resistant enterococci. Appl Environ Microbiol 74, 1997-2003.
79. Misselwitz, B., Schmitt-Willich, H., Ebert, W., Frenzel, T. and Weinmann, H.J. (2001) Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent. MAGMA 12, 128-134.
80. Mota-Meira, M., Morency, H. and Lavoie, M.C. (2005) In vivo activity of mutacin B-Ny266. J Antimicrob Chemother 56, 869-871.
81. Nes, I.F., Diep, D.B. and Holo, H. (2007a) Bacteriocin diversity in Streptococcus and Enterococcus. J Bacteriol 189, 1189-1198.
82. Nes, I.F., Yoon, S.-S. and Diep, D.B. (2007b) Ribosomally synthesized antimicrobial peptides (bacteriocins) in lactic acid bacteria: a review. Food Sci Biotechnol 16, 675-690.
83. NIAID (2001) NIAID Global Health Research Plan for HIV/AIDS, Malaria, and Tuberculosis.
84. Nissen-Meyer, J. and Nes, I.F. (1997) Ribosomally synthesized antimicrobial peptides: their function, structure, biogenesis, and mechanism of action. Arch Microbiol 167, 67-77.
85. Novoa, M.A., Diaz-Guerra, L., San Millan, J.L. and Moreno, F. (1986) Cloning and mapping of the genetic determinants for microcin C7 production and immunity. J Bacteriol 168, 1384-1391.
86. Oman, T.J., Boettcher, J.M., Wang, H., Okalibe, X.N. and van der Donk, W.A. (2011) Sublancin is not a lantibiotic but an S-linked glycopeptide. Nat Chem Biol 7, 78-80.
87. Opsata, M., Nes, I.F. and Holo, H. (2010) Class IIa bacteriocin resistance in Enterococcus faecalis V583: the mannose PTS operon mediates global transcriptional responses. BMC Microbiol 10, 224.
88. Overbye, K.M. and Barrett, J.F. (2005) Antibiotics: where did we go wrong? Drug Discov Today 10, 45-52.
89. Paterson, D.L. (2006) The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43(Suppl 2), S43-S48.
90. Piper, C., Draper, L.A., Cotter, P.D., Ross, R.P. and Hill, C. (2009) A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 64, 546-551.
91. Polak, J., Della Latta, P. and Blackburn, P. (1993) In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 17, 265-270.
92. Postma, P.W., Lengeler, J.W. and Jacobson, G.R. (1993) Phosphoenolpyruvate:carbohydrate phosphotransferase systems of bacteria. Microbiol Rev 57, 543-594.
93. Powers, J.H. (2003) Development of drugs for antimicrobial-resistant pathogens. Curr Opin Infect Dis 16, 547-551.
94. Qiu, X.Q., Wang, H., Lu, X.F., Zhang, J., Li, S.F., Cheng, G., Wan, L., Yang, L., Zuo, J.Y., Zhou, Y.Q., Wang, H.Y., Cheng, X., Zhang, S.H., Ou, Z.R., Zhong, Z.C., Cheng, J.Q., Li, Y.P. and Wu, G.Y. (2003) An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria. Nat Biotechnol 21, 1480-1485.
95. Qiu, X.Q., Zhang, J., Wang, H. and Wu, G.Y. (2005) A novel engineered peptide, a narrow-spectrum antibiotic, is effective against vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 49, 1184-1189.
96. Ramnath, M., Beukes, M., Tamura, K. and Hastings, J.W. (2000) Absence of a putative mannose-specific phosphotransferase system enzyme IIAB component in a leucocin A-resistant strain of Listeria monocytogenes, as shown by two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Appl Environ Microbiol 66, 3098-3101.
97. Ramshaw, J.A., Werkmeister, J.A. and Glattauer, V. (1996) Collagen-based biomaterials. Biotechnol Genet Eng Rev 13, 335-382.
98. Rea, M.C., Dobson, A., O'Sullivan, O., Crispie, F., Fouhy, F., Cotter, P.D., Shanahan, F., Kiely, B., Hill, C. and Ross, R.P. (2010a) Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci USA 108(Suppl 1), 4639-4644.
99. Rea, M.C., Dobson, A., O'Sullivan, O., Crispie, F., Fouhy, F., Cotter, P.D., Shanahan, F., Kiely, B., Hill, C. and Ross, R.P. (2010b) Microbes and Health Sackler Colloquium: effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci USA 15, 4639-4644.
100. Rea, M.C., Sit, C.S., Clayton, E., O'Connor, P.M., Whittal, R.M., Zheng, J., Vederas, J.C., Ross, R.P. and Hill, C. (2010c) Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci USA 107, 9352-9357.
101. Rea, M.C., Ross, R.P., Cotter, P.D. and Hill, C. (2011) Classification of bacteriocins from Gram-positive bacteria. In Prokaryotic Antimicrobial Peptides - from Genes to Applications ed. Drider, D. and Rebuffat, S. pp. 29-53. New York: Springer.
102. Reynolds, R., Potz, N., Colman, M., Williams, A., Livermore, D. and MacGowan, A. (2004) Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 53, 1018-1032.
103. Rogers, B.A., Aminzadeh, Z., Hayashi, Y. and Paterson, D.L. (2011) Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. Clin Infect Dis 53, 49-56.
104. Ross, A.C. and Vederas, J.C. (2011) Fundamental functionality: recent developments in understanding the structure-activity relationships of lantibiotic peptides. J Antibiot (Tokyo) 64, 27-34.
105. Rossi, L.M., Rangasamy, P., Zhang, J., Qiu, X.Q. and Wu, G.Y. (2008) Research advances in the development of peptide antibiotics. J Pharm Sci 97, 1060-1070.
106. Saier, M.H. Jr and Paulsen, I.T. (1999) Paralogous genes encoding transport proteins in microbial genomes. Res Microbiol 150, 689-699.
107. Salomon, R.A. and Farias, R.N. (1992) Microcin 25, a novel antimicrobial peptide produced by Escherichia coli. J Bacteriol 174, 7428-7435.
108. Schaffner, W., Melly, M.A., Hash, J.H. and Koenig, M.G. (1967) Lysostaphin: an enzymatic approach to staphylococcal disease I. In vitro studies. Yale J Biol Med 39, 215-229.
109. Shah, A., Mond, J. and Walsh, S. (2004) Lysostaphin-coated catheters eradicate Staphylococcus aureus challenge and block surface colonization. Antimicrob Agents Chemother 48, 2704-2707.
110. Shingadia, D. and Novelli, V. (2003) Diagnosis and treatment of tuberculosis in children. Lancet Infect Dis 3, 624-632.
111. Skaugen, M., Nissen-Meyer, J., Jung, G., Stevanovic, S., Sletten, K., Inger, C., Abildgaard, M. and Nes, I.F. (1994) In vivo conversion of L-serine to D-alanine in a ribosomally synthesized polypeptide. J Biol Chem 269, 27183-27185.
112. Smith, L. and Hillman, J. (2008) Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Curr Opin Microbiol 11, 401-408.
113. Spellberg, B., Powers, J.H., Brass, E.P., Miller, L.G. and Edwards, J.E. Jr (2004) Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38, 1279-1286.
114. Stein, T., Heinzmann, S., Solovieva, I. and Entian, K.D. (2003) Function of Lactococcus lactis nisin immunity genes nisI and nisFEG after coordinated expression in the surrogate host Bacillus subtilis. J Biol Chem 278, 89-94.
115. Stepper, J., Shastri, S., Loo, T.S., Preston, J.C., Novak, P., Man, P., Moore, C.H., Havlicek, V., Patchett, M.L. and Norris, G.E. (2011) Cysteine S-glycosylation, a new post-translational modification found in glycopeptide bacteriocins. FEBS Lett 585, 645-650.
116. Tenover, F.C. (2010) Potential impact of rapid diagnostic tests on improving antimicrobial use. Ann NY Acad Sci 1213, 70-80.
117. Tessema, G.T., Moretro, T., Kohler, A., Axelsson, L. and Naterstad, K. (2009) Complex phenotypic and genotypic responses of Listeria monocytogenes strains exposed to the class IIa bacteriocin sakacin P. Appl Environ Microbiol 75, 6973-6980.
118. Thankappan, U.P., Madhusudana, S.N., Desai, A., Jayamurugan, G., Rajesh, Y.B. and Jayaraman, N. (2011) Dendritic poly(ether imine) based gene delivery vector. Bioconjug Chem 22, 115-119.
119. Twomey, D.P., Wheelock, A.I., Flynn, J., Meaney, W.J., Hill, C. and Ross, R.P. (2000) Protection against Staphylococcus aureus mastitis in dairy cows using a bismuth-based teat seal containing the bacteriocin, lacticin 3147. J Dairy Sci 83, 1981-1988.
120. Vadyvaloo, V., Hastings, J.W., van der Merwe, M.J. and Rautenbach, M. (2002) Membranes of class IIa bacteriocin-resistant Listeria monocytogenes cells contain increased levels of desaturated and short-acyl-chain phosphatidylglycerols. Appl Environ Microbiol 68, 5223-5230.
121. Vadyvaloo, V., Arous, S., Gravesen, A., Hechard, Y., Chauhan-Haubrock, R., Hastings, J.W. and Rautenbach, M. (2004) Cell-surface alterations in class IIa bacteriocin-resistant Listeria monocytogenes strains. Microbiology (Reading, England) 150, 3025-3033.
122. Verhoef, J. (2003) Antibiotic resistance: the pandemic. Adv Exp Med Biol 531, 301-313.
123. Walsh, C. and Wright, G. (2005) Introduction: antibiotic resistance. Chem Rev 105, 391-394.
124. Walsh, S., Shah, A. and Mond, J. (2003) Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob Agents Chemother 47, 554-558.
125. Walsh, M.C., Gardiner, G.E., Hart, O.M., Lawlor, P.G., Daly, M., Lynch, B., Richert, B.T., Radcliffe, S., Giblin, L., Hill, C., Fitzgerald, G.F., Stanton, C. and Ross, P. (2008) Predominance of a bacteriocin-producing Lactobacillus salivarius component of a five-strain probiotic in the porcine ileum and effects on host immune phenotype. FEMS Microbiol Ecol 64, 317-327.
126. Wester, C.W., Durairaj, L., Evans, A.T., Schwartz, D.N., Husain, S. and Martinez, E. (2002) Antibiotic resistance: a survey of physician perceptions. Arch Intern Med 162, 2210-2216.
127. Wiedemann, I., Breukink, E., van Kraaij, C., Kuipers, O.P., Bierbaum, G., de Kruijff, B. and Sahl, H.G. (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 276, 1772-1779.
128. Wiedemann, I., Bottiger, T., Bonelli, R.R., Wiese, A., Hagge, S.O., Gutsmann, T., Seydel, U., Deegan, L., Hill, C., Ross, P. and Sahl, H.G. (2006) The mode of action of the lantibiotic lacticin 3147- a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol 61, 285-296.
129. Williamson, C.M., Bramley, A.J. and Lax, A.J. (1994) Expression of the lysostaphin gene of Staphylococcus simulans in a eukaryotic system. Appl Environ Microbiol 60, 771-776.
130. Wu, J.A., Kusuma, C., Mond, J.J. and Kokai-Kun, J.F. (2003) Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother 47, 3407-3414.
131. Yoneyama, F., Imura, Y., Ichimasa, S., Fujita, K., Zendo, T., Nakayama, J., Matsuzaki, K. and Sonomoto, K. (2009a) Lacticin Q, a lactococcal bacteriocin, causes high-level membrane permeability in the absence of specific receptors. Appl Environ Microbiol 75, 538-541.
132. Yoneyama, F., Imura, Y., Ohno, K., Zendo, T., Nakayama, J., Matsuzaki, K. and Sonomoto, K. (2009b) Peptide-lipid huge toroidal pore, a new antimicrobial mechanism mediated by a lactococcal bacteriocin, lacticin Q. Antimicrob Agents Chemother 53, 3211-3217.
133. Yuan, C.T., Dembry, L.M., Higa, B., Fu, M., Wang, H. and Bradley, E.H. (2009) Perceptions of hand hygiene practices in China. J Hosp Infect 71, 157-162.
134. Zhao, T., Doyle, M.P., Harmon, B.G., Brown, C.A., Mueller, P.O. and Parks, A.H. (1998) Reduction of carriage of enterohemorrhagic Escherichia coli O157:H7 in cattle by inoculation with probiotic bacteria. J Clin Microbiol 36, 641-647.
135. Zygmunt, W.A. and Tavormina, P.A. (1972) Lysostaphin: model for a specific enzymatic approach to infectious disease. Prog Drug Res 16, 309-333.